Enhancing effect of Labrasol on the intestinal absorption of ganciclovir in rats

References

• Laskin OL, Cederberg DM, Mills J, Eron LJ, Mildvan D, Spector SA. (1987). Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med, 83:201–207.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Kanwar M. (2002). Ocular preparations: The formulation approach. Drug Dev Ind Pharm, 28:473–493.
   PubMed Web of Science ®Google Scholar
• Morse GD, Shelton MJ, O’Donnell AM. (1993). Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet, 24:101–123.
   PubMed Web of Science ®Google Scholar
• Spector SA, Busch DF, Follansbee S, Squires K, Lalezari JP, Jacobson MA et al. (1995). Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: A phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. J Infect Dis, 171:1431–1437.
   PubMed Web of Science ®Google Scholar
• Kenley RA, Jackson SE, Winterle JS, Shunko Y, Visor GC. (1986). Water soluble complexes of the antiviral drugs, 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine and acyclovir: The role of hydrophobicity in complex formation. J Pharm Sci, 75:648–653.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Firestone BA, Bergstrom R, Fass M, Massey I, Tsina I et al. (1987). Selection of a derivative of the antiviral agent 9-[(1,3-dihydroxy-2-propoxy)-methyl]guanine (DHPG) with improved oral absorption. Pharm Res, 4:120–125.
   PubMed Web of Science ®Google Scholar
• Jezyk N, Rubas W, Grass GM. (1992). Permeability characteristics of various intestinal regions of rabbit, dog, and monkey. Pharm Res, 9:1580–1586.
   PubMed Web of Science ®Google Scholar
• Chiou WL, Barve A. (1998). Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res, 15:1792–1795.
   PubMed Web of Science ®Google Scholar
• Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB. (1995). Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther, 17:425–432.
   PubMed Web of Science ®Google Scholar
• Liu H, Pan W, Ke P, Dong Y, Ji L. (2010). Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. Drug Dev Ind Pharm, 36:1098–1105.
   PubMed Web of Science ®Google Scholar
• Kleymann G. (2003). Novel agents and strategies to treat herpes simplex virus infections. Expert Opin Investig Drugs, 12:165–183.
   PubMed Web of Science ®Google Scholar
• Ueda K, Yoshida A, Amachi T. (1999). Recent progress in P-glycoprotein research. Anticancer Drug Des, 14:115–121.
   PubMedGoogle Scholar
• Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. (1996). Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol, 48:1083–1089.
   PubMed Web of Science ®Google Scholar
• Mallick S, Pattnaik S, Swain K, De PK. (2007). Current perspectives of solubilization: Potential for improved bioavailability. Drug Dev Ind Pharm, 33:865–873.
   PubMed Web of Science ®Google Scholar
• Palmberger TF, Hombach J, Bernkop-Schnürch A. (2008). Thiolated chitosan: Development and in vitro evaluation of an oral delivery system for acyclovir. Int J Pharm, 348:54–60.
   PubMed Web of Science ®Google Scholar
• Salama NN, Scott KR, Eddington ND. (2004). DM27, an enaminone, modifies the in vitro transport of antiviral therapeutic agents. Biopharm Drug Dispos, 25:227–236.
   PubMed Web of Science ®Google Scholar
• Yang ZG, Meng H, Zhang X, Li XD, Lv WL, Zhang Q. (2004). Effect of quercetin on the acyclovir intestinal absorption. Beijing Da Xue Xue Bao, 36:309–312.
   PubMedGoogle Scholar
• Kreilgaard M, Pedersen EJ, Jaroszewski JW. (2000). NMR characterisation and transdermal drug delivery potential of microemulsion systems. J Control Release, 69:421–433.
   PubMed Web of Science ®Google Scholar
• Yüksel N, Karatas A, Ozkan Y, Savaser A, Ozkan SA, Baykara T. (2003). Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: In vitro and in vivo evaluation. Eur J Pharm Biopharm, 56:453–459.
   PubMed Web of Science ®Google Scholar
• Rama Prasad YV, Eaimtrakarn S, Ishida M, Kusawake Y, Tawa R, Yoshikawa Y et al. (2003). Evaluation of oral formulations of gentamicin containing Labrasol in beagle dogs. Int J Pharm, 268:13–21.
   PubMed Web of Science ®Google Scholar
• Djordjevic L, Primorac M, Stupar M, Krajisnik D. (2004). Characterization of caprylocaproyl macrogolglycerides based microemulsion drug delivery vehicles for an amphiphilic drug. Int J Pharm, 271:11–19.
   PubMed Web of Science ®Google Scholar
• Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. (2004). Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm, 278:119–131.
   PubMed Web of Science ®Google Scholar
• Lin Y, Shen Q, Katsumi H, Okada N, Fujita T, Jiang X et al. (2007). Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine 123, a P-glycoprotein substrate, in rats. Biol Pharm Bull, 30:1301–1307.
   PubMed Web of Science ®Google Scholar
• Yang Z, Manitpisitkul P, Sawchuk RJ. (2006). In situ studies of regional absorption of lobucavir and ganciclovir from rabbit intestine and predictions of dose-limited absorption and associated variability in humans. J Pharm Sci, 95:2276–2292.
   PubMed Web of Science ®Google Scholar
• Tang C, Yu J, Yin L, Yin C, Pei Y. (2007). Transport of insulin in modified Valia-Chien chambers and Caco-2 cell monolayers. Drug Dev Ind Pharm, 33:449–456.
   PubMed Web of Science ®Google Scholar
• Tomita M, Hayashi M, Awazu S. (1996). Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells. J Pharm Sci, 85:608–611.
   PubMed Web of Science ®Google Scholar
• Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R, Frokjaer S. (2004). Intestinal solute carriers: An overview of trends and strategies for improving oral drug absorption. Eur J Pharm Sci, 21:3–16.
   PubMed Web of Science ®Google Scholar
• König J, Nies AT, Cui Y, Leier I, Keppler D. (1999). Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta, 1461:377–394.
   PubMed Web of Science ®Google Scholar
• Fromm MF. (2003). Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest, 33 Suppl 2:6–9.
   PubMed Web of Science ®Google Scholar
• Li M, Si L, Pan H, Rabba AK, Yan F, Qiu J et al. (2011). Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: Assessed in vitro by everted gut sac and in situ by improved intestinal perfusion. Int J Pharm, 403:37–45.
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Ganapathy V, Leibach FH. (1988). Transport of guanidine in rabbit intestinal brush-border membrane vesicles. Am J Physiol, 255:G85–G92.
   PubMed Web of Science ®Google Scholar
• Hombach J, Hoyer H, Bernkop-Schnürch A. (2008). Thiolated chitosans: Development and in vitro evaluation of an oral tobramycin sulphate delivery system. Eur J Pharm Sci, 33:1–8.
   PubMed Web of Science ®Google Scholar
• Werle M, Hoffer M. (2006). Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release, 111:41–46.
   PubMed Web of Science ®Google Scholar
• Sha X, Yan G, Wu Y, Li J, Fang X. (2005). Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci, 24:477–486.
   PubMed Web of Science ®Google Scholar